Efficacy of Helicobacter pylori eradication therapy in chronic liver disease

Jung, Sung Woo; Lee, S.W.; Hyun, Jong Jin; Kim, D.I.; Koo, Ja Seol; Yim, Hyung Joon; Park, J.J.; Lee, H.S.; Chun, Hoon Jai; Um, Soon Ho; Choi, Jai Hyun; Kim, C.D.; Ryu, Ho Sang

doi:10.1016/j.dld.2008.03.005

Cited by 18 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of peptic ulcer in the cirrhotic patients is reported in the range of 4.3-49%9,10 and in Korean studies, its prevalence was in the range of 24.3% to 38.3% which shows higher compared with the reports from western countries 11,12…”

Section: Introductionmentioning

confidence: 79%

Management of portal hypertensive gastropathy and other bleeding

Chung

2014

Clin Mol Hepatol

View full text Add to dashboard Cite

A major cause of cirrhosis related morbidity and mortality is the development of variceal bleeding, a direct consequence of portal hypertension. Less common causes of gastrointestinal bleeding are peptic ulcers, malignancy, angiodysplasia, etc. Upper gastrointestinal bleeding has been classified according to the presence of a variceal or non-variceal bleeding. Although non-variceal gastrointestinal bleeding is not common in cirrhotic patients, gastroduodenal ulcers may develop as often as non-cirrhotic patients. Ulcers in cirrhotic patients may be more severe and less frequently associated with chronic intake of non-steroidal anti-inflammatory drugs, and may require more frequently endoscopic treatment. Portal hypertensive gastropathy (PHG) refers to changes in the mucosa of the stomach in patients with portal hypertension. Patients with portal hypertension may experience bleeding from the stomach, and pharmacologic or radiologic interventional procedure may be useful in preventing re-bleeding from PHG. Gastric antral vascular ectasia (GAVE) seems to be different disease entity from PHG, and endoscopic ablation can be the first-line treatment.

show abstract

Section: Introductionmentioning

confidence: 79%

Management of portal hypertensive gastropathy and other bleeding

Chung

2014

Clin Mol Hepatol

View full text Add to dashboard Cite

show abstract

“…According to a report on eradication in individuals with chronic hepatitis and hepatic cirrhosis, eradication could be performed with no particular problems in individuals with impaired hepatic function; however, the liver is involved in the metabolization of many drugs used for eradication therapy; thus, such drugs should be used with adequate caution to adverse events.…”

Section: Treatmentmentioning

confidence: 99%

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

et al. 2019

View full text Add to dashboard Cite

Background Since “Helicobacter pylori (H. pylori) infection” was set as the indication in the Japanese Society for Helicobacter Research (JSHR) Guidelines 2009, eradication treatment for H. pylori gastritis is covered under insurance since 2013 in Japan, and the number of H. pylori eradication has rapidly increased. Under such circumstances, JSHR has made the third revision to the “Guidelines for diagnosis and treatment of H. pylori infection” for the first time in 7 years. Methods The Guideline Committee held 10 meetings. Articles published between the establishment of the 2009 Guidelines and March 2016 were reviewed and classified according to the evidence level; the statements were revised on the basis of this review. After inviting public comments, the revised statements were finalized using the Delphi method. Results There was no change in the basic policy that H. pylori infectious disease is an indication for eradication. Other diseases presumed to be associated with H. pylori infection were added as indications. Serum pepsinogen level, endoscopic examination, and X‐ray examination were added to the diagnostic methods. The effects of 1‐week triple therapy consisting of potassium‐competitive acid blocker (P‐CAB), amoxicillin, and clarithromycin have improved, and high eradication rates can also be expected with proton pump inhibitors (PPI) or P‐CAB combined with amoxicillin and metronidazole. If the susceptibility test is not performed, the triple PPI or P‐CAB/amoxicillin/metronidazole therapy should be chosen, because the PPI/amoxicillin/metronidazole combination demonstrated a significantly higher eradication rate than PPI/amoxicillin/clarithromycin. In the proposal for gastric cancer prevention, we divided gastric cancer prevention measures by age from adolescent to elderly, who are at an increased gastric cancer risk, and presented measures for gastric cancer prevention primarily based on H. pylori eradication. Conclusion We expect the revised guidelines to facilitate appropriate interventions for patients with H. pylori infection and accomplish its eradication and prevention of gastric cancer.

show abstract

“…In addition, diagnosing drug-induced liver injury is problematic because of its vague symptoms and lack of definite diagnostic guidelines. Amoxicillin is well known as a safe drug even when administered to patients with chronic liver disease or cirrhosis 15. Therefore, amoxicillin-induced liver injury may not be suspected at an early stage, as in the present case.…”

Section: Discussionmentioning

confidence: 69%

A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage

et al. 2011

View full text Add to dashboard Cite

Amoxicillin, an antibiotic that is widely prescribed for various infections, is associated with a very low rate of drug-induced liver injury; hepatitis and cholestasis are rare complications. Here we present a case of a 39-year-old woman who was diagnosed with abdominal actinomycosis and received amoxicillin treatment. The patient displayed hepatocellular and bile-duct injury, in addition to elevated levels of liver enzymes. The patient was diagnosed with amoxicillin-induced cholestatic hepatitis. When amoxicillin was discontinued, the patient's symptoms improved and her liver enzyme levels reduced to near to the normal range.

show abstract

Efficacy of Helicobacter pylori eradication therapy in chronic liver disease

Cited by 18 publications

References 27 publications

Management of portal hypertensive gastropathy and other bleeding

Management of portal hypertensive gastropathy and other bleeding

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage

Contact Info

Product

Resources

About